[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Fujishiro Y, Nakao K, Watanabe K, Ebihara Y, Nakamura N, Mori H, Hayashi N, Asakage T: A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma. Acta Otolaryngol Suppl; 2007 Dec;(559):151-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.
  • OBJECTIVE: A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer.
  • From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / pathology. Cisplatin / therapeutic use. Maxillary Sinus / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340587.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, Monahan J, Kitamura K, Ichimura K, Ozawa K: Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther; 2001 Feb;8(2):99-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells.
  • However, relatively low efficiency of transgene expression, which is mainly due to a limited second-strand synthesis from the single-stranded AAV genome, can be a problem in some applications that require potent gene expression such as antitumor applications.
  • We demonstrate here that an AAV vector harboring the herpes simplex virus type-1 thymidine kinase (HSVtk) is able to kill cancer cells more efficiently when used in combination with gamma-ray irradiation.
  • A human maxillary sinus cancer cell line, NKO-1, was efficiently killed in combination with HSVtk transduction and ganciclovir (GCV), as expected.
  • These findings suggest that the combination of rAAVtk/GCV suicide gene therapy with radiotherapy has synergistic effects in the treatment of cancers and may lead to a reduction of the potential toxicity of both rAAVtk/GCV and gamma-ray irradiation.
  • [MeSH-major] Antiviral Agents / pharmacology. Carcinoma, Squamous Cell / therapy. Dependovirus / genetics. Ganciclovir / pharmacology. Genetic Therapy / methods. Herpesvirus 1, Human / enzymology. Maxillary Sinus Neoplasms / therapy. Thymidine Kinase / genetics
  • [MeSH-minor] DNA, Single-Stranded / metabolism. Dose-Response Relationship, Radiation. Gamma Rays. Gene Expression / radiation effects. Genetic Vectors. Humans. Lac Operon. Radiation Dosage. Survival Rate. Transgenes. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11263531.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Single-Stranded; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


3. Yokoyama J: [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers].
  • Eighteen N3 cases, fourteen skullbase invasion cases and twenty-six cases of paranasal sinus cancer with orbital invasion were treated by superselective intra-arterial chemotherapy using CDDP and sodium thiosulfate to preserve the organs and to improve poor prognosis.
  • CT-arteriography (CTA) was used to diagnosis all feeding arteries of advanced cancers before infusing CDDP.
  • In three cases with extirpation of the eyeball CTA was not used in the treatment, and CDDP was infused into only the maxillary artery excluding the transverse facial artery.
  • In skullbase invasion cases, the number of complete responses (CR) was 8/14, and that of partial responses (PR) was 6/14.
  • CTA is a very efficient method for diagnosing all feeding arteries of advanced cancers in the superselective intra-arterial chemotherapy.
  • [MeSH-major] Angiography. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiography. Infusions, Intra-Arterial / methods. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Orbital Neoplasms. Paranasal Sinus Neoplasms / drug therapy. Skull Base Neoplasms / drug therapy. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. SODIUM THIOSULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484060.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Thiosulfates; HX1032V43M / sodium thiosulfate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH: Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol; 2005 Feb;125(2):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulindac sulfide-induced apoptosis in sinonasal cancer cells.
  • CONCLUSIONS: These results demonstrate that sulindac sulfide can induce cell death in maxillary cancer cells, and that sulindac sulfide-induced apoptosis is related to the extracellular signal-regulated kinase/p38 MAPK-caspase 3 signaling pathway.
  • OBJECTIVE: Head and neck cancer is the sixth commonest cancer in the human body.
  • Squamous cell carcinoma accounts for most sinonasal cancers.
  • However, little is known regarding the biochemical mechanism(s) of cell death in sinonasal cancers.
  • Recently, human epidemiological and clinical intervention studies have indicated that sulindac, a non-steroidal anti-inflammatory drug, exhibits chemopreventive activity in colorectal cancer.
  • In this study, we aimed to investigate whether sulindac sulfide can induce apoptosis in sinonasal cancer cells and what type of molecular mechanisms induces the death of sinonasal cancer cells.
  • MATERIAL AND METHODS: Sinonasal cancer cells (Asan Medical Center Head and Neck Cancer 5) were treated with various concentrations of sulindac sulfide.
  • RESULTS: Human nasal cavity cancer cells treated with sulindac sulfide underwent cell death, and the induction of apoptosis occurred in a dose-dependent manner.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Paranasal Sinus Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology. Sulindac / therapeutic use
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / administration & dosage. Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Flavonoids / administration & dosage. Flavonoids / pharmacology. Fluorescence. Humans. Imidazoles / administration & dosage. Imidazoles / pharmacology. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Pyridines / administration & dosage. Pyridines / pharmacology. Signal Transduction / drug effects

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880954.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Amino Acid Chloromethyl Ketones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Caspase Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


5. Taussky D, Rufibach K, Huguenin P, Allal AS: Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):684-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for developing a second upper aerodigestive cancer after radiotherapy with or without chemotherapy in patients with head-and-neck cancers: an exploratory outcomes analysis.
  • METHODS AND MATERIALS: The data of 521 patients with a minimum follow-up of 1 year were pooled: 224 patients from the Swiss Group for Clinical Cancer Research (SAKK) 10/94 trial, treated with 1.2 Gy b.i.d. to 74.4 Gy, and randomized to receive or not to receive simultaneous chemotherapy with cisplatin (excluding nasopharyngeal and maxillary sinus carcinomas); and 297 patients from Geneva, all treated with accelerated radiotherapy with concomitant boost to 69.9 Gy and predominantly cisplatin-based concomitant chemotherapy in 33% of patients (including 21 patients with nasopharyngeal carcinomas).
  • CONCLUSIONS: Our data do not suggest that addition of chemotherapy to radiotherapy influences the incidence of second cancers in patients with head-and-neck cancer.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Databases as Topic. Female. Humans. Male. Middle Aged. Regression Analysis. Risk Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936546.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, De Braud F: Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur J Cancer; 2004 Aug;40(12):1872-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase I & II clinical studies gave preliminary indications of activity in melanoma, pancreatic, lung and ovarian cancers.
  • In 1 of 17 evaluable, previously untreated patients, regression of multiple skin lesions was noted with stabilisation of lung metastases and maxillary sinus mass, lasting 155 days.
  • Other drug-related toxicities (G3/4) included: anaemia, thrombocytopenia, nausea, vomiting, diarrhoea, mucositis and fatigue.
  • Further studies with BBR3464 in this tumour type are not recommended.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288289.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BBR 3464; 0 / Organoplatinum Compounds
  •  go-up   go-down






Advertisement